MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients

Gámez‐Pozo, Angelo; Antón-Aparicio, Luis; Bayona, Cristina; Borrega, Pablo; Sancho, María I. Gallegos; García-Domínguez, Rocío; Portugal, Teresa de; Ramos-Vázquez, Manuel; Perez-Carrion, R.; Bolós, Maria Victoria; Madero, Rosário; Sánchez‐Navarro, Iker; Vara, Juan Ángel Fresno; Arranz, Enrique Espinosa

doi:10.1593/neo.12734

Cited by 72 publications

(62 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have analysed the presence of multiple mi RNAs in serum from patients with RCC to provide prognostic information and identify renal-specific cancers [240][241][242] . The use of miRNA profiles to predict treatment response has also been proposed and two studies have identified panels of mi RNAs that are associated with different responses to sunitinib, an FDA-approved treatment for RCC 243,244 .…”

Section: Prognosismentioning

confidence: 99%

The epigenetic landscape of renal cancer

2016

View full text Add to dashboard Cite

| The majority of kidney cancers are associated with mutations in the von Hippel-Lindau gene and a small proportion are associated with infrequent mutations in other well characterized tumour-suppressor genes. In the past 15 years, efforts to uncover other key genes involved in renal cancer have identified many genes that are dysregulated or silenced via epigenetic mechanisms, mainly through methylation of promoter CpG islands or dysregulation of specific microRNAs. In addition, the advent of next-generation sequencing has led to the identification of several novel genes that are mutated in renal cancer, such as PBRM1, BAP1 and SETD2, which are all involved in histone modification and nucleosome and chromatin remodelling. In this Review, we discuss how altered DNA methylation, microRNA dysregulation and mutations in histone-modifying enzymes disrupt cellular pathways in renal cancers.

show abstract

Section: Prognosismentioning

confidence: 99%

The epigenetic landscape of renal cancer

2016

View full text Add to dashboard Cite

show abstract

“…miRNAs are noncoding RNAs that regulate gene expression [57]. Gámez-Pozo et al [57] associated the expression of miRNA combinations (e.g.…”

Section: Micro Rna In Sunitinib Treatmentmentioning

confidence: 99%

“…miRNAs are noncoding RNAs that regulate gene expression [57]. Gámez-Pozo et al [57] associated the expression of miRNA combinations (e.g. hsa-miR-141, hsa-miR-31, hsa-miR-125a-5p) in peripheral blood of RCC patients with poor or prolonged response to sunitinib [57].…”

Section: Micro Rna In Sunitinib Treatmentmentioning

confidence: 99%

A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review

Diekstra

Swen

Gelderblom

et al. 2016

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

“…[65][66][67][68][69][70][71][72][73][74][75][76] Specifically, relatively few studies, including only one multicentre study 67 , have been conducted, and most studies did not perform an internal validation with a training and validation set or even an internal validation approach, such as bootstrapping or cross-validation. Moreover, all studies except one used serum as the source of RNA despite plasma being the blood component of choice since the release of miRNAs from blood cells such as the miRNA-enriched platelets into serum occurs during the coagulation process.…”

Section: [H1] Biofluid Mirnas In Kidney Cancermentioning

confidence: 99%

“…Gamez-Pozo et al 76 performed a particularly interesting study with regard to the use of miRNA signatures for personalizing treatment of metastatic RCC. The investigators examined the miRNA profiles of leucocytes in peripheral blood samples from patients receiving sunitinib for advanced RCC using microarrays.…”

Section: [H1] Biofluid Mirnas In Kidney Cancermentioning

confidence: 99%